Three-drug therapy for light-chain cardiac amyloidosis
Part of Blood & lymphatic, Heart & circulation clinical trials.
This trial tests a combination of three drugs—selinexor, daratumumab, and dexamethasone—for people with a rare condition where abnormal proteins build up in the heart. The goal is to see if this combination can help reduce these proteins and improve heart function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of light-chain amyloidosis, which means abnormal proteins (amyloid) are found in your tissues.
- Your heart is affected by the amyloidosis, shown by a thickened heart wall or by a high NT-proBNP level in your blood.
- Your condition is at a certain stage (Mayo stage IIIa or IIIb), meaning it is advanced but you may be newly diagnosed or your disease has come back after treatment.
- You have measurable levels of abnormal protein in your blood.
- You are not pregnant or breastfeeding, and if you are of childbearing age, you agree to use birth control during the study and for 4 weeks after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called CAR-NK cells for people with amyloidosis that has affected the heart. The treatment uses specially modified immune cells to target and attack the abnormal protein deposits causing the disease. It may be an option for people who haven't responded well to standard treatments.
This trial tests an experimental treatment using your own immune cells, modified in the lab, to target and destroy the cells that cause AL amyloidosis. It is for people who are newly diagnosed and have severe heart involvement, with the goal of slowing or stopping the disease.
This trial tests a combination of two drugs (teclistamab and daratumumab) for people with AL amyloidosis who have not had prior treatment. The goal is to see if this combination can safely and effectively reduce the abnormal protein deposits in organs.
This trial tests a new drug combination for people with a specific type of AL amyloidosis (light chain amyloidosis) that has a genetic marker called t(11;14). The treatment includes Sonrotoclax (a targeted therapy) plus steroids, and possibly another drug called daratumumab, to see if it can help control the disease.
This trial tests a new drug called NXC-201 against a standard combination treatment (daratumumab with cyclophosphamide, bortezomib, and dexamethasone) for people with newly diagnosed AL amyloidosis. The goal is to see if the new drug works better at targeting the abnormal proteins that cause organ damage.
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
Hear when a new Light-chain Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.